In a disease such as chronic myeloid leukemia (CML), shared treatment decision-making between providers and patients is key, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.
In a disease such as chronic myeloid leukemia (CML), shared treatment decision-making between providers and patients is key, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.
Transcript
What are the potential benefits of patient involvement in treatment decision-making for both the patients and health care providers?
Especially in CML, where we're talking about compounds and medications [that] have been taken over several years, an involved and shared decision-making is quite important in order to ensure compliance, and by ensuring compliance, you ensure efficacy. So if you want to treat and conduct your CML therapy properly, you have to make sure that you have an informed consent within this treatment.
What should providers keep in mind when involving patients in CML treatment decision-making, particularly when presenting multiple treatment options to patients?
It's quite difficult, so I think you have to decide beforehand which medication opportunities are there, and then you have to narrow to the most important points. So it's not like saying, "We've got to 5 medications at hand, so just choose one." That's got [to be], "We have this medication with these kinds of advantages, and there are these specific side effects," and that overall comes together to find a shared decision.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More